144 related articles for article (PubMed ID: 20663134)
21. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.
Deng X; Liu H; Huang J; Cheng L; Keller ET; Parsons SJ; Hu CD
Cancer Res; 2008 Dec; 68(23):9663-70. PubMed ID: 19047143
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models.
Husain SR; Kawakami K; Kawakami M; Puri RK
Mol Cancer Ther; 2003 Mar; 2(3):245-54. PubMed ID: 12657719
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
[TBL] [Abstract][Full Text] [Related]
24. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
25. Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer.
Arvanitis DA; Lianos E; Soulitzis N; Delakas D; Spandidos DA
Oncol Rep; 2004 Nov; 12(5):1131-7. PubMed ID: 15492805
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
27. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
Chakrabarti R; Robles LD; Gibson J; Muroski M
Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the cell-specific expression of parathyroid hormone-related protein in normal and neoplastic prostate tissue.
Wu G; Iwamura M; di Sant'Agnese PA; Deftos LJ; Cockett AT; Gershagen S
Urology; 1998 May; 51(5A Suppl):110-20. PubMed ID: 9610565
[TBL] [Abstract][Full Text] [Related]
29. Expression patterns of potential therapeutic targets in prostate cancer.
Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
31. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.
Yu X; Xu X; Han B; Zhou R
Pathol Oncol Res; 2009 Mar; 15(1):91-6. PubMed ID: 18752043
[TBL] [Abstract][Full Text] [Related]
32. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Hamdy FC; Autzen P; Robinson MC; Horne CH; Neal DE; Robson CN
Cancer Res; 1997 Oct; 57(19):4427-31. PubMed ID: 9331107
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
34. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?
Shah R; Mucci NR; Amin A; Macoska JA; Rubin MA
Am J Pathol; 2001 May; 158(5):1767-73. PubMed ID: 11337374
[TBL] [Abstract][Full Text] [Related]
35. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia.
Cockett AT; di Sant'Agnese PA; Gopinath P; Schoen SR; Abrahamsson PA
Urology; 1993 Nov; 42(5):512-9. PubMed ID: 7694415
[TBL] [Abstract][Full Text] [Related]
36. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
37. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
38. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
39. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
[TBL] [Abstract][Full Text] [Related]
40. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
